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ABSTRACT
Objective: To determine the prevalence, risk factors, and functional impairment associated with
peripheral neuropathy in a prospective cohort of adults in rural Uganda.
Methods: Eight hundred participants (400 HIV2 and 400 antiretroviral-naive HIV1) in the Rakai
Community Cohort Study underwent detailed neurologic evaluations including assessment of
neuropathy symptoms, functional measures (Patient Assessment of Own Functioning Inventory
and Karnofsky Performance Status scores), and neurologic evaluation by a trained medical offi-
cer. Neuropathy was defined as $1 subjective symptom and $1 sign of neuropathy on examina-
tion. Neuropathy risk factors were assessed using log binomial regression.
Results: Fifty-three percent of participants were men, with a mean (SD) age of 35 (8) years. Neu-
ropathy was present in 13% of the cohort and was more common in HIV1 vs HIV2 participants
(19% vs 7%, p , 0.001). Older age (relative risk [RR] 1.04, 95% confidence interval [CI] 1.02–
1.06), female sex (RR 1.49, 95% CI 1.04–2.15), HIV infection (RR 2.82, 95% CI 1.86–4.28),
tobacco use (RR 1.59, 95% CI 1.02–2.48), and prior neurotoxic medication use (RR 2.08, 95%
CI 1.07–4.05) were significant predictors of neuropathy in the overall cohort. Only older age was
associated with neuropathy risk in the HIV1 (RR 1.03, 95% CI 1.01–1.05) and HIV2 (RR 1.06,
95% CI 1.02–1.10) cohorts. Neuropathy was associated with impaired functional status on
multiple measures across all participant groups.
Conclusions: Peripheral neuropathy is relatively common and associated with impaired functional
status among adults in rural Uganda. Older age, female sex, and HIV infection significantly
increase the risk of neuropathy. Neuropathy may be an underrecognized but important condition
in rural Uganda and warrants further study. Neurology® 2017;89:485–491
GLOSSARY
ARV 5 antiretroviral; CES-D 5 Center for Epidemiologic Studies–Depression Scale; CI 5 confidence interval; HAND 5 HIV-
associated neurocognitive disorders; PAOFI 5 Patient Assessment of Own Functioning Inventory; RR 5 relative risk.
Neurologic complications of HIV infection are common, and peripheral neuropathy is the most
common neurologic disorder among HIV1 adults.1,2 Large systematic studies of neuropathy
from resource-constrained settings are lacking, and available studies report widely varying
neuropathy rates (e.g., 4% in South Africa, 59% in Rwanda).3,4 Importantly, neuropathy rates
and severity in resource-constrained settings may differ from those seen in Western contexts
because of different antiretroviral (ARV) initiation guidelines, a limited range of available ARV
drugs, differences in diet and nutrition, unique environmental exposures, use of other neuro-
toxic medications such as isoniazid, and differing rates of comorbidities. A better understanding
of neuropathy prevalence and risk factors in sub-Saharan African populations are crucial as this is
where the majority of the world’s HIV1 individuals reside. The WHO estimates that almost 26
million people in sub-Saharan Africa are living with HIV, accounting for 70% of the world’s 37
million HIV1 persons.5 Improved knowledge of neuropathy risk factors in this population is
imperative to reduce the burden of disease and develop better future treatments for neuropathy.
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The goal of this study was to determine the
rate of and risk factors for neuropathy among
both HIV1 and demographically matched
HIV2 adults in rural Uganda, a country with
a national HIV prevalence of 7.1% and
approximately 1.5 million HIV1 persons in
2015.6 This represents the largest study to date
of ARV-naive HIV1 adults in an outpatient
setting in rural sub-Saharan Africa.
METHODS Study participants. Study participants were
drawn from the Rakai Community Cohort Study, an open,
community-based cohort of adults residing in 50 communities in
Rakai District, which is representative of rural Uganda. Eligible
participants were $20 years old and in 1 of 3 patient groups: (1)
HIV1 ARV-naive adults with advanced immunosuppression (CD4
#200 cells/mL); (2) HIV1 ARV-naive adults with moderate
immunosuppression (CD4 350–500 cells/mL); and (3)HIV2 adults
who were age-, sex-, and community-matched to the HIV1 par-
ticipants. (This cohort was also designed to study the effect of HIV
subtype on the development of HIV-associated neurocognitive dis-
orders [HAND]. The CD4 strata were used to select participants for
assessment of HAND and were not selected specifically for this
substudy of neuropathy.) Exclusion criteria included severe systemic
illness, inability to provide informed consent, physical disability re-
sulting in an inability to travel to the main Rakai Health Sciences
Program clinic, and plans to leave Rakai District within 2 years of
enrollment. Leprosy was not a specific exclusion criterion, but no
patients with obvious skin lesions of leprosy were included in the
study. In addition, while leprosy still occurs in Uganda, it primarily
occurs in northern parts of the country and is uncommon in Rakai
District, which is located in the south-central region.7
Study procedures. Participants were enrolled in this observa-
tional cross-sectional cohort study between August 2013 and
July 2015. Each consenting participant completed a sociodemo-
graphic and behavioral interview, depression screen (Center for
Epidemiologic Studies–Depression Scale [CES-D]8), functional
status assessments (Patient Assessment of Own Functioning
Inventory [PAOFI]9 and Karnofsky Performance Status10), and
the Timed Gait Test.11 The Modified Total Neuropathy Scale
was also administered.12,13 A Ugandan medical officer (i.e.,
a physician who has completed an internship but no residency
training) who was trained specifically for the evaluation of
peripheral neuropathy by 2 US neurologists (D.S., N.S.) per-
formed a neuromedical evaluation including assessment of sub-
jective neuropathy symptoms and examination of strength, ankle
reflexes, vibratory sensation, and pinprick sensation. Participants
also underwent a peripheral blood draw for confirmation of HIV
status and, in HIV1 participants, for determination of CD4 cell
count. Fasting glucose, comprehensive metabolic panels, and
fasting lipids were also obtained for each participant.
Standard protocol approvals, registrations, and patient
consents. Written informed consent for participating in the
Table 1 Characteristics by patient group
Overall
(n 5 800)
By HIV status By CD4 count
HIV1
(n 5 400)
HIV2
(n 5 400) p Value
<200
(n 5 200)
350-500
(n 5 200) p Value
Male, n (%) 422 (53) 212 (53) 210 (52) 0.89 121 (60) 91 (46) 0.003a
Age, y, mean (SD) 35 (8) 35 (8) 35 (8) 0.88 34 (7) 37 (9) 0.001a
Average CD4 count, mean (SD) — — — — 95 (61) 420 (43) ,0.001a
BMI, mean (SD) 22.5 (3.7) 21.8 (3.5) 23.2 (3.9) ,0.001a 20.6 (2.8) 23.0 (3.7) ,0.001a
Underweight, n (%) 80 (10) 51 (13) 29 (7) 0.01a 44 (22) 7 (4) ,0.001a
Overweight/obese, n (%) 151 (19) 53 (13) 98 (25) ,0.001a 7 (4) 46 (23) ,0.001a
Tobacco use, n (%) 105 (13) 63 (16) 42 (10) 0.03a 39 (20) 24 (12) 0.04a
Narcotics use, n (%) 15 (2) 12 (3) 3 (1) 0.02a 10 (5) 2 (1) 0.02a
Alcohol use in last month, n (%) 381 (48) 195 (49) 186 (46) 0.52 90 (45) 105 (52) 0.13
Diabetes, n (%) 3 (0.3) 0 (0) 3 (1) 0.08 — — —
Hypertension, n (%) 16 (2) 4 (1) 12 (3) 0.04a 0 (0) 4 (2) 0.04a
Traditional medication use, n (%) 18 (2) 8 (2) 10 (2) 0.64 5 (2) 3 (2) 0.48
Neurotoxic medication use, n (%) 27 (3) 17 (4) 10 (2) 0.17 6 (3) 11 (6) 0.22
INH use, n (%) 19 (2) 11 (3) 8 (2) 0.49 3 (2) 8 (4) 0.13
Dapsone use, n (%) 4 (0.5) 4 (1) 0 (0) 0.04a 2 (1) 2 (1) 1
Metronidazole use, n (%) 5 (0.6) 3 (1) 2 (0.5) 0.65 1 (0.5) 2 (1) 0.56
Karnofsky Performance Score, mean (SD) 93 (7) 91 (8) 94 (6) ,0.001a 89 (8) 93 (8) ,0.001a
CES-D Score, mean (SD) 7.9 (8.6) 10.1 (9.4) 5.6 (7.2) ,0.001a 11.7 (9.6) 8.5 (8.8) 0.001a
PAOF total 148 (17) 147 (18) 148 (15) 0.42 150 (16) 145 (20) 0.009a
Abbreviations: BMI 5 body mass index; CES-D 5 Center for Epidemiologic Studies Depression Scale; INH5 isoniazid; PAOFI5 Patient Assessment of Own
Functioning Inventory.
a Significant.
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study was obtained from all study participants. This study was
approved by the Johns Hopkins Institutional Review Board,
the Uganda Virus Research Institute Research and Ethics Com-
mittee, and the Uganda National Council for Science and
Technology.
Statistical analysis. Peripheral neuropathy was defined as $1
subjective neuropathy symptom (numbness, paresthesias, or pain
in the hands or feet) and$1 sign of neuropathy (distal weakness,
reduced or absent ankle reflexes, abnormal distal vibratory sensa-
tion, or abnormal distal pinprick sensation) on examination. This
definition was chosen to minimize false-positives as many par-
ticipants reported transient tingling but had no objective signs of
neuropathy on examination. In addition, because many partic-
ipants did not regularly wear shoes or regularly engage in manual
labor, there was concern that foot calluses would interfere with
portions of the sensory examination. As such, the decision was
made to require both signs and symptoms in the definition of
neuropathy.
Comparative analyses between participant groups and
between participants with and without neuropathy were per-
formed using x2 tests for categorical variables and t tests for
continuous variables. Log-binomial regression was performed to
determine significant predictors of neuropathy. Analyses were
performed using STATA version 10.1 (StataCorp, College
Station, TX).
RESULTS Eight hundred participants were enrolled,
of whom 400 were HIV2, 200 were HIV1 with
advanced immunosuppression (CD4 count ,250
cells/mL), and 200 were HIV1 with moderate
immunosuppression (CD4 count 350–500 cells/
mL) (table 1). Of all participants, 53% were male
with a mean (SD) age of 35 (8) years. Nearly half
(48%) of all participants reported alcohol use in the
last month, with 13% reporting tobacco use and 2%
reporting illicit drug use, which consisted primarily of
poppy seeds and marijuana (there is very little IV drug
use in the Rakai District). Compared to HIV2
participants, HIV1 participants had a lower body
mass index (21.8 vs 23.2, p , 0.001), and reported
more tobacco (16% vs 10%, p5 0.03) and drug (3%
vs 1%, p5 0.02) use. Other significant demographic
differences between participant groups are detailed in
table 1.
Table 2 Neuropathy characteristics by patient group, n (%)
Overall
(n 5 800)
By HIV status By CD4 count
HIV1
(n 5 400)
HIV2
(n 5 400) p Value
<200
(n 5 200)
350-500
(n 5 200) p Value
Neuropathy symptoms
Any sensory neuropathy symptom 247 (31) 161 (40) 86 (22) ,0.001a 77 (38) 84 (42) 0.45
Paresthesias 226 (28) 150 (38) 76 (19) ,0.001a 75 (38) 75 (38) 1
Numbness 212 (26) 142 (36) 70 (18) ,0.001a 68 (34) 74 (37) 0.53
Pain 82 (10) 46 (12) 36 (9) 0.24 22 (11) 24 (12) 0.75
Motor symptoms 62 (8) 42 (10) 20 (5) 0.004a 25 (12) 17 (8) 0.19
Fatigue 148 (18) 113 (28) 35 (9) ,0.001a 85 (42) 28 (14) ,0.001a
Neuropathy signs
Any neuropathy sign on examination 263 (33) 161 (40) 102 (26) ,0.001a 81 (40) 80 (40) 0.95
Any distal weakness 29 (4) 23 (6) 6 (2) 0.001a 19 (10) 4 (2) 0.001a
Reduced/absent ankle reflex 56 (7) 34 (8) 22 (6) 0.09 18 (9) 16 (8) 0.73
Abnormal vibration 197 (25) 118 (30) 79 (20) 0.001a 50 (25) 68 (34) 0.04a
Abnormal pinprick 55 (7) 39 (10) 16 (4) 0.001a 22 (11) 17 (8) 0.41
Timed gait, s, mean (SD) 12.3 (2.4) 12.7 (2.7) 11.8 (2.0) ,0.001a 13.2 (3.2) 12.2 (2.0) ,0.001a
Neuropathy prevalence
Neuropathy 5 any sign 1 any symptom 103 (13) 76 (19) 27 (7) ,0.001a 36 (18) 40 (20) 0.59
Symptoms only, no signs 144 (18) 85 (21) 59 (15) 0.02a 41 (20) 44 (22) 0.69
Asymptomatic but signs present 160 (20) 85 (21) 75 (19) 0.37 45 (22) 40 (20) 0.56
Modified Total Neuropathy Scale
No neuropathy 393 (49) 154 (38) 239 (60) ,0.001a 81 (40) 73 (36) 0.81
Mild neuropathy 399 (50) 239 (60) 160 (40) 116 (58) 123 (62)
Moderate neuropathy 5 (0.6) 4 (1) 1 (0.2) 2 (1) 2 (1)
Severe neuropathy 3 (0.4) 3 (1) 0 (0) 1 (0.5) 2 (1)
a Significant.
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Neuropathic symptoms and signs were common
in the cohort, with each occurring in approximately
one-third of patients (table 2). However, both were
more common among HIV1 than HIV2 partici-
pants. Overall, 31% of participants reported neuro-
pathic pain symptoms (HIV1 40%; HIV2 22%;
p, 0.001) and 33% of participants had objective signs
of neuropathy on examination (HIV1 40%; HIV2
26%; p , 0.001). Because the definition of periph-
eral neuropathy required the presence of both symp-
toms and signs, 13% of participants overall met this
criterion, which was significantly more common
among HIV1 (19%) than HIV2 participants (7%,
p , 0.001). HIV1 participants were more likely to
have moderate or severe neuropathy than their HIV2
counterparts as assessed by the Modified Total Neu-
ropathy Score.
Risk factors for neuropathy are shown in table 3.
In the overall cohort, older age, female sex, HIV
infection, tobacco use, and prior neurotoxic medica-
tion use were significantly associated with neuropa-
thy, with HIV infection conferring the strongest risk
(relative risk [RR] 2.82; 95% confidence interval [CI]
1.86–4.28, p , 0.001). Older age was the only sig-
nificant predictor among HIV1 (RR 1.03, 95% CI
1.01–1.05, p 5 0.002) and HIV2 (RR 1.06, 95%
CI 1.02–1.10, p 5 0.002) participants. In addition,
advanced immunosuppression was not a significant
predictor in the HIV cohort (RR 0.90, 95% CI
0.60–1.34, p5 0.59). A history of diabetes was asso-
ciated with higher risk of neuropathy among HIV2
participants, but this did not reach significance (RR
5.09, 95% CI 0.98–26.3, p 5 0.052), although this
may have been due to the small number of partici-
pants with diabetes. Fasting glucose, liver function
tests, creatinine, blood urea nitrogen level, and vari-
ous other measures of alcohol consumption (e.g., self-
reported days of alcohol use per month, number of
alcoholic drinks per day, alcohol abuse) did not vary
by neuropathy status in any participant group (data
not shown).
Participants with peripheral neuropathy showed
significant functional impairment by multiple meas-
ures when compared to participants without neurop-
athy (table 4). In the overall cohort, participants with
neuropathy were more likely to report fatigue (32%
vs 16%, p 5 0.04), had slower timed gait (12.8 sec-
onds vs 12.2 seconds, p 5 0.04), scored lower on the
PAOFI (143 vs 148, p 5 0.001), had lower Karnof-
sky Performance Status scores (89 vs 93, p , 0.001),
and had higher depression scores on the CES-D (11.8
vs 7.3, p , 0.001). All of these differences were also
significant within the HIV2 cohort except for the
PAOFI scores. Among HIV1 participants, those
with neuropathy had lower PAOFI and Karnofsky
Performance Status scores and higher CES-D scores,
but there was no significant difference between re-
ported fatigue or timed gait.
DISCUSSION This study of adults in rural Uganda
revealed high rates of symptomatic neuropathy
(19%) among HIV1 participants with an additional
20% of participants having objective signs but no
symptoms of neuropathy. This rate is within the
range of those found in other studies of HIV-
associated peripheral neuropathy from sub-Saharan
Africa, which ranged from 4% among HIV1 ARV-
naive South African adults to 60% among HIV1
Rwandan outpatients on ARV therapy.3,4 However,
most prior studies have found neuropathy rates of
Table 3 Risk factors associated with neuropathy by patient group
Overall population (n 5 800) HIV1 population (n 5 400) HIV2 population (n 5 400)
RR of neuropathy,
RR (95% CI) p Value
RR of neuropathy,
RR (95% CI) p Value
RR of neuropathy,
RR (95% CI) p Value
Female sex 1.49 (1.04–2.15) 0.03a 1.39 (0.92–2.08) 0.12 1.88 (0.88–4.00) 0.1
Age, y 1.04 (1.02–1.06) ,0.001a 1.03 (1.01–1.05) 0.002a 1.06 (1.02–1.10) 0.002a
HIV1 2.82 (1.86–4.28) ,0.001a — — — —
CD4 count <200 — 0.90 (0.60–1.34) 0.59 — —
Height, m 0.37 (0.04–3.64) 0.4 1.25 (0.10–14.8) 0.86 0.01 (0.0001–1.36) 0.07
BMI 1.01 (0.96–1.06) 0.72 1.02 (0.97–1.08) 0.34 1.05 (0.96–1.15) 0.29
Tobacco use 1.59 (1.02–2.48) 0.04a 1.42 (0.88–2.30) 0.15 1.48 (0.54–4.08) 0.45
Alcohol use 1.2 (0.78–1.61) 0.52 1.06 (0.70–1.58) 0.79 1.24 (0.60–2.57) 0.56
History of diabetes 2.60 (0.52–13.02) 0.24 — — 5.09 (0.98–26.3) 0.052
Prior neurotoxic medication use 2.08 (1.07–4.05) 0.03a 1.58 (0.74–3.40) 0.24 3.12 (0.85–11.40) 0.08
Abbreviations: BMI 5 body mass index; CI 5 confidence interval; RR 5 relative risk determined using log binomial regression.
a Significant.
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10%–40%, including studies from Ethiopia,14
Kenya,15–17 Nigeria,18,19 Rwanda,20 Uganda,21,22 and
Zimbabwe.21,22 Much of the variability likely results
from the diversity of patient populations studied as
most cohorts included both ARV-naive HIV1 par-
ticipants and those who had initiated ARV therapy.
Study settings varied from exclusively outpatient to
inpatient settings, and some included participants
from both settings. In addition, the methods used to
diagnose neuropathy varied widely from assessment
by a neurologist to diagnoses based on peripheral
neuropathy screening tools. The most commonly
used screening tools were the Brief Peripheral Neu-
ropathy Screen and Subjective Peripheral Neuropathy
Screen, which have primarily been validated in the
United States but have variable diagnostic utility in
resource-limited settings.15,16,20,23,24
A South African study of HIV1 outpatients, which
included both ARV-naive and ARV-experienced par-
ticipants, identified symptomatic neuropathy in 30%
of participants with 50% of participants having objec-
tive signs of neuropathy on examination.25 These find-
ings are similar to this study, in which 19% of
participants had symptomatic neuropathy and 40%
had objective signs of neuropathy. The slightly higher
rates observed in the South African participants may be
attributable to neurotoxic effects of ARV therapy as
many first-line ARVmedications in sub-Saharan Africa,
such as stavudine, confer additional risk of develop-
ing neuropathy. Similar differences were found
in Kenyan cohorts, in which neuropathy rates rose
from 11% in ARV-naive to 36% among HIV1
ARV-experienced outpatients.16,17 These findings
suggest that neuropathy rates among HIV1 adults
in rural Uganda who have initiated ARV therapy may
be even higher than those reported in this study.
Of note, 7% of HIV2 participants in our cohort
met criteria for neuropathy, with an additional 20%
of HIV2 participants having objective signs of neu-
ropathy on examination without concurrent
symptoms. These rates were much higher than ex-
pected given that this cohort included relatively
young and healthy adults with low rates of diabetes,
renal disease, and liver disease. A prior study of
HIV1 participants matched to HIV2 controls in
Nigeria found no cases of neuropathy among the
100 controls they studied.19 Epidemiologic data
of overall peripheral neuropathy rates not linked
to one particular etiology are sparse. However,
a population-based study in Bombay in which
participants who screened positive for neuropathy
symptoms on a door-to-door survey were evaluated by
a neurologist found an overall neuropathy prevalence of
2.4%, which is much lower than that observed in Ra-
kai.26 Furthermore, many known neuropathy risk fac-
tors, including alcohol use, height, and prior neurotoxic
medication use, were not associated with neuropathy risk
in this study, suggesting that other unstudied risk factors
may account for high rates of neuropathy observed in
this cohort. Nutritional deficiencies, environmental ex-
posures, and other infectious etiologies may at least par-
tially account for the high neuropathy rate observed in
this study but were not assessed in this cohort.
Among HIV1 participants in Rakai, older age was
associated with neuropathy. Older age was signifi-
cantly associated with increased neuropathy risk in
other HIV1 cohorts in Uganda, Zimbabwe, Kenya,
and Ethiopia.14,16,17,19,21,22 Female sex was also associ-
ated with higher risk of neuropathy in all subgroups,
although this association was only significant among
the overall cohorts. Overall, the effect of sex on neu-
ropathy is controversial. Studies from Kenya, Uganda,
and Zimbabwe report an increased neuropathy risk
among female participants, but other cohorts from
Uganda, Zimbabwe, and Nigeria have found no
association.14,21,22 One study of 150 HIV1 Kenyan
outpatients initiating ARV therapy found that
women were at 10-fold increased risk of developing
neuropathy after ARV initiation than their male
counterparts, an effect that was partially attenuated
Table 4 Relationship of fatigue, motor, depression, and functional impairment to neuropathy by patient group, mean (SD)
Overall population (n 5 800) HIV1 population (n 5 400) HIV2 population (n 5 400)
Neuropathy
(n 5 103)
No
neuropathy
(n 5 697) p Value
Neuropathy
(n 5 76)
No
neuropathy
(n 5 323) p Value
Neuropathy
(n 5 27)
No
neuropathy
(n 5 173) p Value
Fatigue, n (%) 33 (32) 155 (16) ,0.001a 25 (33) 88 (27) 0.32 8 (30) 27 (7) ,0.001a
Timed gait 12.8 (2.8) 12.2 (2.3) 0.04a 12.7 (2.6) 12.7 (2.7) 0.9 13.1 (3.2) 11.8 (1.8) 0.04a
CES-D 11.8 (9.8) 7.3 (8.3) ,0.001a 12.3 (10.0) 9.6 (9.1) 0.03a 10.4 (9.2) 5.3 (6.9) 0.008a
PAOFI total score 143 (18) 148 (16) 0.001a 142 (20) 148 (18) 0.01a 143 (12) 149 (15) 0.05
Karnofsky Performance Scale
score
89 (8) 93 (7) ,0.001a 89 (8) 91 (8) 0.02a 90 (8) 95 (6) 0.004a
Abbreviations: CES-D 5 Center For Epidemiologic Studies–Depression Scale; PAOFI 5 Patient Assessment of own Functioning Inventory.
aSignificant.
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by the increased neuropathy risk associated with low
hemoglobin levels.17 A study of both HIV1 and
HIV2 adult women in Rwanda found that approx-
imately half of women in both groups reported neu-
ropathy symptoms.27 These rates were so much
higher than expected that the authors posit the rates
must be due to overreporting among women,
although no objective measures of neuropathy were
evaluated to validate this claim. In our study, the
diagnosis required both subjective symptoms and
objective signs of neuropathy. However, there was
no difference in rates of objective signs of neuropathy
by sex, which suggests that women may be more
likely to report neuropathy symptoms than men.
The absence of a sex difference in objective signs of
neuropathy observed in this cohort suggests under-
reporting of symptoms by men rather than overre-
porting by women.
One unexpected finding in this study was that there
was no relationship between CD4 count and neurop-
athy. In the United States, markers of HIV disease
severity, such as low CD4 count and high viral load,
have consistently been linked to neuropathy risk.28,29
Studies from sub-Saharan Africa have found no asso-
ciation between CD4 count or duration of HIV infec-
tion with peripheral neuropathy.4,19,22,25 Taken
together, these findings suggest that factors other than
those related to HIV disease severity may be contrib-
uting to neuropathy rates in sub-Saharan Africa.
Peripheral neuropathy among both HIV1 and
HIV2 participants in Rakai was significantly linked
to poorer functional status, as has been previously
observed in the United States and in other regions of
sub-Saharan Africa. For example, in the CNS HIV
Antiretroviral Therapy Effects Research Study
(CHARTER), neuropathy was associated with reduced
quality of life, unemployment, and disability in activ-
ities of daily living.29 Another cohort of nearly 1,000
HIV1 adults in the United States found that neurop-
athy was associated with worsened health status,
decreased work productivity, and increased health care
utilization.30 While a study from Nigeria found no
association between neuropathy and overall mortality
in HIV1 adults, a Rwandan study found that neurop-
athy was associated with reduced quality of life in both
physical and psychological domains.19,20
This study has several limitations. First, the diagno-
sis of peripheral neuropathy was based entirely on clin-
ical findings. Given the resource limitations in rural
Uganda, we were unable to obtain skin biopsies, nerve
conduction studies, quantitative sensory testing, or
other electrophysiologic measures of neuropathy to
correlate with the clinical data obtained. In addition,
the neurologic evaluation was completed by non-
neurologist physicians. However, these physicians
received in-person training on assessing neuropathy
signs from US-trained neurologists (D.S., N.S.) before
the study began and at regular intervals throughout the
study. Concomitant diagnoses of conditions predispos-
ing to neuropathy, such as diabetes and thyroid dys-
function, were based only on self-report and are
likely underdiagnosed in this rural setting. In addition,
our study did not include measures of nutritional sta-
tus, such as dietary surveys, household income infor-
mation, or laboratory markers such as mean
corpuscular volume. As a result, nutritional deficiencies
as risk factors for neuropathy, which may be important
contributors in this population, were not fully ad-
dressed. Finally, given local resource constraints, a thor-
ough laboratory investigation to assess for causes of
peripheral neuropathy was not possible.
This study is important for several reasons. First, it
represents one of the largest systematic assessments of
peripheral neuropathy in rural sub-Saharan Africa.
Inclusion of age-, sex-, and community-matched
HIV2 participants also offered the opportunity to
compare predisposing factors for neuropathy while
adequately controlling for the effect of HIV. Further-
more, investigating the prevalence of neuropathy in
an ambulatory population is more likely to accurately
represent the true population prevalence because neu-
ropathies associated with acute illnesses, which may
be common in hospitalized patients, are not included.
Finally, the frequency of neuropathy in the HIV1
individuals is not confounded by the use of neuro-
toxic ARV therapy as all HIV1 individuals were
ARV-naive at the time of evaluation.
Given the high rates of neuropathy seen in our
study and others from sub-Saharan Africa as well as
the significant association of neuropathy with lost
productivity, worsened health status, and reduced
quality of life, HIV2associated neuropathy is likely
a major cause of morbidity in sub-Saharan Africa and
likely contributes substantially to lost productivity
and health care utilization in this region. Further
investigation is needed to determine unique risk fac-
tors for neuropathy in both HIV1 and HIV2 adults
in this region, and the effect of ARV therapy on
neuropathy for the HIV1 individuals. In addition,
research is urgently needed to improve the treatment
of neuropathy in order to reduce the negative effects
of neuropathy at an individual, family, community,
and societal level in sub-Saharan Africa.
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